NTRA
NasdaqNATERA, INC.
Healthcare · Services-Medical Laboratories
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$625.5M
2021
$820.2M
2022
$1.1B
2023
$1.7B
2024
$2.3B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$2.3B
Net Income$-208.2M
Gross Profit—
Oper Income$-309.9M
EPS (dil)$-1.52
Rev/sh$16.10
FCF/sh$0.76
Book/sh$11.96
Gross M—
Oper M-13.4%
Profit M-9.0%
FCF M4.7%
ROE-12.2%
ROA-8.7%
ROIC-26.2%
R&D/Rev27.1%
Rev Y/Y35.9%
Rev 3Y CAGR41.1%
EPS Y/Y0.7%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+9.6%
Current Ratio3.39
Quick Ratio3.24
Debt/Eq0.17
Int Coverage-76.2×
Net Debt$793.2M cash
Total Debt$282.9M
Cash & Eq$1.1B
Total Assets$2.4B
Oper CF$215.3M
Capex$106.2M
Free CF$109.1M
Buybacks—
Equity$1.7B
Liabilities$685.9M
Shs Outstand0.14B
SectorHealthcare
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $625.5M | $820.2M | $1.1B | $1.7B | $2.3B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-468.2M | $-541.0M | $-446.2M | $-222.3M | $-309.9M |
| Net Income | $-471.7M | $-547.8M | $-434.8M | $-190.4M | $-208.2M |
| Diluted EPS | $-5.21 | $-5.57 | $-3.78 | $-1.53 | $-1.52 |
| Operating Cash Flow | $-335.2M | $-431.5M | $-247.0M | $135.7M | $215.3M |
| Free Cash Flow | $-376.3M | $-479.2M | $-286.2M | $69.2M | $109.1M |
COMMUNITY · $NTRA0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.